Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer.
Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer.
复制标题
与 II-III 期结肠癌患者生存相关的遗传变异。
DOI：
10.1016/j.cgh.2019.11.046
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Goldberg,Richa
中科院分区：
文献类型：
--
作者：
Penney,KathrynL;Banbury,BarbaraL;Bien,Stephanie;Harrison,TabithaA;Hua,Xinwei;Phipps,AmandaI;Sun,Wei;Song,Mingyang;Joshi,AmitD;Alberts,StevenR;Allegra,CarmenJ;Atkins,James;Colangelo,LindaH;George,ThomasJ;Goldberg,Richa
Background & AimsMany genetic variants have been associated with colorectal cancer risk, although few have been associated with survival times of patients. Identification of genetic variants associated with survival times might improve our understanding of disease progression and aid in outcome prediction. We performed a genome-wide association study to identify variants associated with colon cancer survival time.MethodsWe performed a post hoc analysis of data from NCCTG N0147 (Alliance), a randomized phase 3 trial of patients with resected stage III colon cancer, and from NSABP C-08 (NRG), a phase 3 trial that compared therapy regimens for patients with resected stage II or III colon cancer. Genotype analyses were performed on DNA from blood samples from 4974 patients. We used Cox proportional hazards regression to evaluate the association of each single nucleotide polymorphism with times of overall survival and disease-free survival, adjusting for age at diagnosis, sex, treatment group, and principal components of genetic ancestry. We performed the analysis for studies N0147 and C-08 separately, and results were combined in a fixed-effects meta-analysis.ResultsA locus on chromosome 7p15.2 was significantly associated with overall survival time (P≤ 5x10–08). The most significant variant at this locus, rs76766811 (P = 1.6x10–08), is common among African Americans (minor allele frequency, approximately 18%) but rare in European Americans (minor allele frequency <0.1%). Within strata of self-reported ancestry, this variant was associated with times of overall survival and disease-free survival in only African Americans (hazard ratio for overall survival, 2.82; 95% CI, 1.88–4.23;P= 5.0x10–07and hazard ratio for disease-free survival, 2.27; 95% CI, 1.62–3.18; P = 1.8x10–06).ConclusionsIn an analysis of data from 2 trials of patients with stage II or III colon cancer, we identified rs76766811 as a potential prognostic variant in African American patients. This finding should be confirmed in additional study populations. ClinicalTrials.gov Identifiers: NCT00096278 (NSABP C-08) and NCT00079274 (NCCTG N0147).
